To Whom it may concern
May 16, 2019
Ohara Pharmaceutical Co., Ltd.
Announcement of a Strategic Capital and Business AllianceAgreement with Fidson Healthcare Plc.
— Strategic partnership with the largest local pharmaceutical company
in Nigeria—
We are pleased to announce that Ohara Pharmaceutical Co., Ltd. (Head office:Koka City, Shiga, President and CEO: Seiji Ohara, hereinafter referred to as the“Company”) and Fidson Healthcare Plc. (Head office: Federal Republic ofNigeria, CEO: Dr. Fidelis Ayebae, hereinafter referred to as “Fidson”) executeda strategic capital and business alliance agreement effective as of April 4, 2019.

1. Strategic capital and business alliance
The Company is expected to acquire an equity shareholding of approximately
20% in Fidson (subject to final statutory approvals) through a participation in an
equity financing recently implemented by Fidson, which will make Fidson an
equity method affiliate of the Company.
As strategic partners, the Company and Fidson, a major pharmaceuticalmanufacturer in Nigeria, have concluded a capital and business allianceagreement that aims to provide the respective markets to which each company
serves with the latest healthcare products and services.

More specifically, theCompany will aim to provide new pharmaceuticals and medical devices whichprimarily target childhood cancers that the Company has been developing, as
well as generic pharmaceuticals, medical devices, etc. from other Asian
pharmaceutical manufacturers with which the Company is currently establishingalliances. These products will be supplied by the Company through aOhara Pharmaceutical Co., Ltd.

distribution network to be established through partners, such as trading
companies, who have the capability to support this alliance.
2. Background
As of 2017, the world population stands at 7.55 billion, of which Africa makes up
1.26 billion. It is predicted that the population of Africa will rapidly increase anddouble by 2050, reaching 2.53 billion among a world population of 9.77 billion.
This means that approximately one in four of the world population will live inAfrica in 2050.

Of these African nations, Nigeria is the most populous nation

with approximately 190 million people. It is predicted Nigeria’s population willgrow to 400 million in 2050, overtaking the U.S. as the world’s third mostpopulous country. (*1)
Provided this background, the role of domestic pharmaceutical manufacturers inAfrica will become critical to support its citizen’s health and well-being. We
believe that sharing the technology, know-how and the various network that theCompany possesses, together with its future partnerships with other Asian andAfrican manufacturers, will enable this partnership to deliver strong growth forboth companies in the future.

[Ohara Pharmaceutical Co., Ltd.]
Ohara Pharmaceutical Co., Ltd. is a pharmaceutical company focusing on thebusinesses of orphan drugs and generic drugs. Its mid-term 3-year businessplan started in FY2018 under the catchphrase “Challenge 2020,” with the key
objective of “addressing unmet medical needs,” to advance management
innovations and make the next leap forward. The company focuses on thedevelopment and marketing of orphan drugs mainly in the field of pediatriconcology and on the development, manufacture and marketing of generic drugs
that give extra consideration to the prevention of medical accidents. Ohara
plans to further expand these businesses into emerging countries, primarily in
the Asian and African regions.

Ohara Pharmaceutical Co., Ltd.

[Fidson Healthcare Plc.]
Fidson Healthcare Plc. is a major pharmaceutical company based in Nigeria,
and was established in 1995.

Fidson went public in 2008.

Fidson handles over 100 types of medicine, and conducts the development,production and sales of OTC drugs and prescription drugs, with strong
distribution infrastructures spread widely throughout Nigeria. Moreover, havingcGMP-compliant manufacturing facilities, Fidson is one of a few Nigerian
pharmaceutical companies that are candidates for a WHO-GMP certification.
Reference data:*1: UN DESA (United Nations Department of Economic and Social Affairs)“The World Population Prospects: The 2017 Revision”

Contact information
Ohara Pharmaceutical Co., Ltd.
Representatives: Iyo, Sawai
TEL: 03-6740-7701
FAX: 03-6740-7702

Ohara Pharmaceutical Co., Ltd.